Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group.

J Hepatol. 2014 Dec;61(6):1238-46. doi: 10.1016/j.jhep.2014.07.022. Epub 2014 Jul 24.

PMID:
25064437
2.

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates.

Wang X, Hruska M, Chan P, Ahmad A, Freeman J, Horga MA, Hillson J, Kansra V, Lopez-Talavera JC.

J Clin Pharmacol. 2015 Jan;55(1):63-72. doi: 10.1002/jcph.363. Epub 2014 Jul 24.

PMID:
25043197
3.

Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables.

Hruska M, Wang X, Chan P, Ahmad A, Freeman J, Horga MA, Hillson J, Kansra V, Lopez-Talavera JC.

J Clin Pharmacol. 2015 Jan;55(1):73-80. doi: 10.1002/jcph.361. Epub 2014 Jul 24.

PMID:
25042797
4.

Pegylated interferons Lambda-1a and alfa-2a display different gene induction and cytokine and chemokine release profiles in whole blood, human hepatocytes and peripheral blood mononuclear cells.

Freeman J, Baglino S, Friborg J, Kraft Z, Gray T, Hill M, McPhee F, Hillson J, Lopez-Talavera JC, Wind-Rotolo M.

J Viral Hepat. 2014 Jun;21(6):e1-9. doi: 10.1111/jvh.12243.

PMID:
24827902
5.

Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.

Furie R, Nicholls K, Cheng TT, Houssiau F, Burgos-Vargas R, Chen SL, Hillson JL, Meadows-Shropshire S, Kinaszczuk M, Merrill JT.

Arthritis Rheumatol. 2014 Feb;66(2):379-89. doi: 10.1002/art.38260.

PMID:
24504810
6.

Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.

Wofsy D, Hillson JL, Diamond B.

Arthritis Rheum. 2013 Jun;65(6):1586-91. doi: 10.1002/art.37940.

7.

Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.

Wofsy D, Hillson JL, Diamond B.

Arthritis Rheum. 2012 Nov;64(11):3660-5. doi: 10.1002/art.34624.

8.

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial.

Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG.

Arthritis Res Ther. 2012 Feb 7;14(1):R33. doi: 10.1186/ar3738.

9.

Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?

Magliano M, Isenberg DA, Hillson J.

Arthritis Rheum. 2002 Aug;46(8):1997-2009. Review. No abstract available.

10.

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.

Moreland L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, Tesser J, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U.

Arthritis Res. 2001;3(4):247-52. Epub 2001 Apr 10.

11.

Rofecoxib.

Hillson JL, Furst DE.

Expert Opin Pharmacother. 2000 Jul;1(5):1053-66. Review.

PMID:
11249495
12.

Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design.

Hillson JL, Furst DE.

Rheum Dis Clin North Am. 1997 Nov;23(4):757-78. Review.

PMID:
9361154
13.

An unbiased analysis of V(H)-D-J(H) sequences from B-1a, B-1b, and conventional B cells.

Kantor AB, Merrill CE, Herzenberg LA, Hillson JL.

J Immunol. 1997 Feb 1;158(3):1175-86.

PMID:
9013957
14.

Analysis of three new idiotypes on human monoclonal autoantibodies.

Kalsi JK, Ravirajan CT, Wiloch-Winska H, Blanco F, Longhurst CM, Williams W, Chapman C, Hillson J, Youniou P, Latchman D, et al.

Lupus. 1995 Oct;4(5):375-89.

PMID:
8563732
15.

Development of the antibody repertoire as revealed by single-cell PCR of FACS-sorted B-cell subsets.

Kantor AB, Merrill CE, MacKenzie JD, Herzenberg LA, Hillson JL.

Ann N Y Acad Sci. 1995 Sep 29;764:224-7. No abstract available.

PMID:
7486528
16.

The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A.

Hillson JL, Karr NS, Oppliger IR, Mannik M, Sasso EH.

J Exp Med. 1993 Jul 1;178(1):331-6.

17.

Emerging human B cell repertoire. Influence of developmental stage and interindividual variation.

Hillson JL, Oppliger IR, Sasso EH, Milner EC, Wener MH.

J Immunol. 1992 Dec 1;149(11):3741-52.

PMID:
1331240
18.

Sequence analysis and idiotypic relationships of BEG-2, a human fetal antibody reactive with DNA.

Watts RA, Hillson JL, Oppliger IR, Mackenzie L, Lydyard PM, Mackworth Young CG, Brown C, Staines NA, Isenberg DA.

Lupus. 1991 Nov;1(1):9-17.

PMID:
1845365
19.

Molecular basis of an autoantibody-associated restriction fragment length polymorphism that confers susceptibility to autoimmune diseases.

Olee T, Yang PM, Siminovitch KA, Olsen NJ, Hillson J, Wu J, Kozin F, Carson DA, Chen PP.

J Clin Invest. 1991 Jul;88(1):193-203.

20.

Autoantibodies and the fetal antibody repertoire.

Hillson JL, Perlmutter RM.

Int Rev Immunol. 1990;5(3-4):215-29. Review.

PMID:
2130118
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk